Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203770 | 0.92 | MEN1 (0.56) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2203539 | 0.86 | MET (0.51) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2200432 | 0.81 | ATM (0.61) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2202976 | 0.79 | PIM1 (0.50) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2203345 | 0.78 | PIM1 (0.62) | PIM1METKDRATM | |
| SCHEMBL2201605 | 0.77 | ATM (0.53) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2203015 | 0.74 | ATM (0.53) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2200567 | 0.73 | KDM4E (0.51) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL23920032 | 0.72 | PIM1 (0.71) | PIM1MEN1KMT2AMETKDR | |
| SCHEMBL2591224 | 0.72 | KDM4E (0.73) | PIM1MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1846402-A1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006063805-A1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER SCHERING PHARMA AKTINGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | MAP4K2, ABL1, MAP4K3 | PIM1 507/4885MEN1 1704/4885KMT2A 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.